Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Nove

At the current valuation, the market is more optimistic about Aldeyra's approach to RASP and prospects for lead program reproxalap. Click here to see why ALDX is a Buy.

Related Keywords

Massachusetts , United States , Bruce Greenberg , Todd Brady , Stephen Machatha , Joshua Reed , Allergan Abbvie , Cubist Pharmaceuticals , Amgen , Ligand Pharmaceuticals , Cydex Pharmaceuticals , Kala Pharmaceuticals , Novartis , Aldeyra Therapeutics , Eye Summary , Controller Bruce Greenberg , Perceptive Advisors , Chief Development Officer Stephen Machatha , Synageva Biopharmaceuticals , Massachusetts Eye , Ear Infirmary ,